Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside

Value Capital Research 25 Followers Follow Summary Thermo Fisher Scientific is rated a Buy, supported by accelerating organic growth and improving Pharma and Biotech end markets. TMO’s recent acquisitions of Clario and Solventum’s Filtration and Separation business expand capabilities, enabling greater share of customer spending and revenue synergies. Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins, with Pharma and Biotech driving mid-single-digit gains. Valuation is reasonable versus peers and history; with 9-10% expected EPS growth and potential for multiple expansion, risk/reward appears attractive. JHVEPhoto/iStock Editorial via Getty Images Investment Thesis Thermo Fisher Scientific's ( TMO ) end markets have begun to rebound from a relatively muted period with organic revenue growth accelerating to 5% in Q2 2026. Pharma and Biotech, which currently accounts for about This article was written by Value Capital Research 25 Followers Follow I am a generalist investor with a long-term investment horizon and prior experience covering multiple sectors for a family office. My investment approach centers on identifying undervalued opportunities across a broad range of industries, including Industrials, Consumer Goods, Technology, and Financial Services. I believe studying multiple sectors provides a deeper understanding of cross-industry trends, capital cycles, and macroeconomic turning points than a narrowly specialized approach.My philosophy is rooted in value investing, with a strong emphasis on identifying catalysts capable of unlocking intrinsic value. Determining whether a company is fundamentally sound is only part of the equation. Equally important is understanding when and why the market will recognize those fundamentals and reprice the business accordingly.My research primarily focuses on companies positioned at the extreme ends of the cycle. This includes businesses trading near cyclical troughs, where expectations and sentiment remain depressed despite significant recovery potential, as well as companies operating near cyclical peaks where valuations appear disconnected from underlying fundamentals.I write on Seeking Alpha to engage with disciplined, rational investors who value in-depth fundamental research, margin-of-safety analysis, and valuation-driven investing. I believe the strongest investment ideas are those capable of withstanding rigorous scrutiny and contrary viewpoints. Through open discussion and critical debate, I aim to continuously refine my own decision-making process while providing readers with data-driven investment research rather than surface-level narratives. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.